China (Mainland)
Premiumsupplier 
CI-994 CAS NO.112522-64-2
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C
- Available Specifications:
≥98.0%(100-500)Gram≥98.0%(1000-5000)Gram
- Product Details
Keywords
- CI-994
- 4-acetylamino-n-(2'-aminophenyl)benzamide;Benzamide, 4-(acetylamino)-N-(2-aminophenyl)-;acetyldinaline;Tacedinaline;CI 994;N-Acetyldinaline;4-AcetaMido-N-(2-aMinophenyl)benzaMide;Cl-994(Tacedinalin,N-
- 112522-64-2
Quick Details
- ProName: CI-994
- CasNo: 112522-64-2
- Molecular Formula: C15H15N3O2
- Appearance: off white powder
- Application: CAS：112522-64-2； Apoptosis Inducers;I...
- DeliveryTime: 3 months
- PackAge: 100g,500g,1kg,25kg/drum
- Port: shang hai
- ProductionCapacity: 1000 Gram/Month
- Purity: 98%
- Storage: Dry seal
- Transportation: shipping
- LimitNum: 100 Gram
Superiority
We are committed to provide excellence in researching, manufacturing and drug discovery process.
Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.
Details
CI-994 (Tacedinaline) is an anti-cancer drug which inhibits HDAC1 with IC50 of 0.57 μM and causes G1 cell cycle arrest.
IC50 Value: 0.57 uM (For HDAC1,MTT assay)
Target: HDAC1
in vitro: Different CI-994 concentrations were tested, ranging from 0.01 to 160 microM at 24, 48, and 72 h of treatment inA-549 (adenocarcinoma) and LX-1 (squamous cell carcinoma) ,with MTT assay. A concentration-dependent cell survival inhibition was observed, with an IC50 at 80 microM. The effect of CI-994, as demonstrated by recovery experiments, was cytostatic and seemed to be superimposable in both cell lines. Cytofluorimetric analysis to assess cell cycle perturbation and apoptosis was performed after 24 h of treatment, indicating a cell block with concomitant increase at G0/G1 phase, a reduction at S phase level at 20, 40, 80, and 160 microM, and apoptosis at the higher concentration (160 microM) [1].
in vivo: CI-994 had the same spectrum of activity in vivo as dinaline. It also behaved similarly in schedule comparison/toxicity trials. Prolonged administration with lower drug doses was more effective than short-term therapy at higher individual doses. If doses were kept between 40 and 60 mg/kg/injection, prolonged administration (> 50 days) was tolerated with no gross toxicity. Doses > or = 90 mg/kg/injection caused lethality after 4-5 days of administration[2]. IC994 is currently in Phase I/II clinical trials, combining with gemcitabine[3].
Clinical trail: CI-994 is in Phase III clinical trial in patients with Lung Cancer.